-
Sonoma Pharmaceuticals filed a registration statement for the potential sale of up to $63.4 million in securities, as reported in Fidelity.
-
The securities include common shares, preferred shares, debt securities, warrants and units, according to the filing.
-
Net proceeds from the sale will be used for general corporate purposes, including working capital, capital expenditures, as well as research and development.
To read more NewsPoints articles, click here.
